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Abstract The aim of this multicenter study was to assess
the pattern and the characteristics of advanced cancer
patients admitted to hospices. A consecutive sample of
patients admitted in a period of 6 months was taken into
consideration. Two hundred thirty-six patients admitted to
hospices were consecutively assessed. Ninety-six percent of
patients were admitted in acute hospital in the previous
3 months, with a mean time spent in hospital of 34.5 days,
and 47 % of patients had received chemotherapy the month
before hospice admission. Thirty-four percent of patients for
whom data were available had significant persistent pain,
and 44 % of them presented episodes of breakthrough pain.
Sixty-one percent of patients were receiving opioid drugs at
admission, and 70 % the day before death, with parenteral
morphine and transdermal fentanyl being the opioids most
frequently administered. The mean admission time in hos-
pice was 18.4 days. Eighty-six percent died in hospice.
Palliative sedation was performed in 25 % of patients who
died in hospice. The short survival and the number of
patients dying in hospice were the principal finding, as it
appears that hospice admission is only one way for end of
life treatments. Patients receive specialized palliative care
only for 2–3 weeks before death, implying an inacceptable
timing for patients with several problems presumed to be
present early during the course of disease. Data from hos-
pice activities in Italy strongly suggest to spread palliative
care in other settings, other than home care and hospice, to
intercept oncologic patients in their disease trajectory early.
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Introduction
Palliative care was initiated in Italy at the end of the 1970s
as a natural progression from an interest in pain control to a
growing importance to resolve other problems for cancer
patients, particularly in the advanced stage of disease. Dur-
ing 1980s, various organizations, usually charities or no-
profit organizations, developed different models of home
care for patients with advanced stage disease [1]. In the last
decade, there have been investments in the field of commu-
nity care and health districts under the input of new legis-
lations, and new resources from the health care system have
been allocated for palliative care. Active centers involved in
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palliative care progressively increased with a large distribu-
tion in Northern Italy, and more than 200 hospices are now
available for cancer and non cancer palliative care pop-
ulation [2]. However, data regarding the clinical activity
in traditional hospices have never been assessed. The
only existing data regard an inpatient acute palliative
care unit, which represent an exception, because it pro-
vides supportive care during all the entire period of
disease, only a minority of patients are admitted in the
final phase of life, and most patients are discharged
home or will continue their oncologic treatments [3,
4]. Italy represents a unique country for its specificity
in cultural issues, attitudes, organization, and health care
system. In fact, palliative care has been recognized by a
specific law only in the last years, and negative atti-
tudes for opioid consumption are well known. More-
over, the sociocultural tissue and health care system
cannot be considered equal to other European countries.
The aim of this multicenter study was to assess the
pattern and the characteristics of advanced cancer patients
admitted to traditional hospices with long-term facilities, as
well as their treatment at the end of life.
Methods
Four hospices participated into the study. These four hos-
pices were selected according to a similar number of beds,
admissions, structures, territorial aspects, users, and health
care professionals, and could be considered representative
of Italian hospices, which are prevalently distributed in the
North. A consecutive sample of patients admitted in a period
of 6 months (from January to June 2011) was taken into
consideration. Data of hospice admissions were prospective-
ly collected, and a specific form was designed for this
purpose. Informed consent from patients or relatives and
ethical committee approval were obtained. Epidemiological
data, including marital status and caregiver availability,
were recorded. The number of admissions and days spent
in hospital in the last 3 months, as well the reasons for
hospital admission and days elapsed from the last chemo-
therapy were collected.
Patients were divided according to the principal indica-
tion for hospice admission, including social problems, un-
controlled pain, uncontrolled symptoms other than pain, end
of life care, and others. Once patients were admitted, they
were asked about pain and its intensity (on a numerical scale
of 0–10), breakthrough pain and its intensity, and analgesics
prescribed. These data were also collected on the day before
death. The duration of hospice admission, the frequency of
discharge home, or frequency of death in hospice were
recorded. Finally, the use of palliative sedation, its duration,
and drugs used on the day of death were recorded.
Statistical analysis
Statistical analysis of quantitative and qualitative data, includ-
ing descriptive statistics, was performed for all the items.
Continuous data were expressed as mean ± standard deviation,
unless otherwise specified. The linear regression and multiple
logistic regression models were used to analyze the relation
between the mean admission time in hospice and continuous
and categorical variables, respectively. Data were analyzed by
the Epi Info software (version 6.0, CDC, Atlanta, GA, US) and
the SPSS Software 14.0 version (SPSS, Inc.,Chicago, Ill, US).
All P values were two-sided and P values less than 0.05 were
considered to indicate statistical significance.
Results
The characteristics of patients are described in Table 1. The
civil status was available in 223 patients: 113 patients were
married, 70 patients were widow, 24 patients were single, 14
patients were divorced, and 2 were common-law partners.
Caregivers were available for 215 patients and were spouse
65, adult children 102, other relatives 32, friends or health-
care workers 14, and nonrelated 2. Of the 211 patients who
provided an answer, 203 patients (96 %) had been admitted
in acute hospital in the previous 3 months, with a mean time
spent in hospital of 34.5 (SD 37.8) days: 110 patients were
admitted once, 73 patients twice, 18 patients three times,
and 2 patients four times. One hundred twelve patients
(47 %) had received chemotherapy the month before hos-
pice admission.
Indications for hospice admission, available in 205
patients, are presented in Table 2. Seventy-eight of 230
(34 %) patients for whom data were available had signifi-
cant persistent pain (>4/10 on a numerical scale), and 44 %
of them presented episodes of breakthrough pain. The mean
Table 1 Characteristics
of advanced cancer
patients admitted to
hospice
Number of
patients
236
Gender
(male/female)
119/117
Age 73 (range 37–100,
SD 11.6)
Primary diagnosis
Gastrointestinal 47
Genitourinary 46
Lung 44
Liver 22
Breast 18
Head–neck 15
Pancreas 13
Others 27
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pain intensity of patients who had persistent pain at
hospice admission was 4.2 (SD 2.4), and the mean
breakthrough pain intensity was 8 (SD 2.2). Of the entire
sample of 236 patients, 144 of them (61 %) were receiv-
ing analgesic drugs. Parenteral morphine and transdermal
fentanyl were the opioids most frequently administered at
hospice admission (48 and 44 patients, respectively) in
mean doses of 71 mg/day, and 51.3 μg/h, respectively.
Eighteen patients were administered immediate or sus-
tained release of oxycodone in mean doses of 60 mg/
day. Oral morphine (immediate or sustained release for-
mulations) was administered in seven patients in mean
doses of 50 mg/day. Five patients were receiving trans-
dermal buprenorphine in mean doses of 45 μg/h. One
patient was receiving oral hydromorphone. Nineteen
patients were receiving different preparations of codeine
or tramadol, and two patients were receiving non-opioid
analgesics. Thirteen patients were receiving more anal-
gesics. Ninety-six patients had a prescription of analge-
sics for breakthrough pain. Forty-one patients were
receiving parenteral morphine (at a mean dose 14 mg,
SD 14) and 27 were given oral morphine (mean a dose
14 mg, SD 10). Only two patients were receiving rapid
onset opioids (transmucosal fentanyl citrate and fentanyl
buccal tablet). The remaining patients were receiving
tramadol, codeine, or non-opioid drugs, in different
preparations.
The day before dying, 165 patients (70 %) received
opioid drugs. Most of them were administered parenter-
al morphine (114 patients, in mean doses of 63 mg/day)
or transdermal fentanyl (28 patients, in mean doses of
48 mcg/h). Eight patients received different formulations
of oxycodone (in mean doses of 25 mg/day), and two
patients received transdermal buprenorphine. The
remaining patients were receiving codeine or tramadol
preparations.
The day before dying, 28 of 90 patients (31 %) with
available data had episodes of breakthrough pain. The
most frequent prescription was parenteral morphine while
transmucosal, buccal, and sublingual fentanyl were pre-
scribed in one, three, and two patients, respectively.
The mean admission time in hospice was 18.4 (SD 15.4)
days. Two hundred two patients (86 %) died in hospice, and
the remaining were discharged home.
Palliative sedation was performed for untreatable symp-
toms in 25 % of patients who died in hospice. The main
reason was a state of agitation and/or dyspnea (75 %). In 76
and 24 % of cases, palliative sedations were performed
giving drugs intravenously and subcutaneously, respective-
ly. Midazolam alone or in combination was used in 87 % of
patients. Hyoscine was added in 9.6 % of patients. Neuro-
leptics were administered alone or in combination in 15 %
of patients. Only one patient was receiving morphine with-
out midazolam of neuroleptics. The mean duration of palli-
ative sedation was 2.5 (SD 3.3) days.
No differences among the centers were found. In an
analysis of linear and multiple logistic regression for con-
tinuous and categorical variables, no significant relationship
for age, gender, marital status, caregiver, hospital admission
in the last 3 months, background pain intensity, and doses of
opioids was found (see Table 3). Presence of background
pain and breakthrough pain episodes at hospice admission
was significantly associated with short survival. Pain inten-
sity of breakthrough pain episodes at hospice admission was
significantly associated with short survival. No correlation
was found with background pain intensity the day before
death, opioid doses for background pain the day before
death, or pain intensity of breakthrough pain episodes and
before death (see Table 3).
Discussion
This study showed the pattern and the characteristics of ad-
vanced cancer patients admitted to a hospice in Italy. The first
relevant findings are the short survival (about 18 days) and the
number of patients dying in hospice. It is likely that these
figures are even higher as some patients are often discharged
home “agonic”, under the pressure of relatives, according to
national cultural attitudes. From these data, it appears that
hospice admission is only one way for end of life treatments.
Of interest, in the last 3 months before hospice admission,
most of them were admitted to hospital and spent about 1/3 of
this period in hospital, and half of them received chemother-
apy in the last month of life. Thus, home care and hospice
patients receive specialized palliative care only for 2–3 weeks
before death, implying an inacceptable timing for patients
with several problems presumed to be present early during
the course of disease. This is confirmed by the large number of
hospital admissions in different acute settings expected to not
providing specialized palliative care resulting in a low level of
cost-effectiveness. This observation can also explain the low
opioid consumption traditionally reported in Italy [5]. It is
unknown whether patients were admitted to hospices from
Table 2 Principal indi-
cations for hospice ad-
mission (available in
205 patients)
Control of other symptoms 103
Pain control 49
Cachexia 20
Anemia 14
Unspecified surgical problems 6
Social problems 5
Reassessment (laboratory or
imaging)
6
Opioid toxicity 1
Chemotherapy 1
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inpatient settings or lack of home care availability. On the
other hand, some palliative interventions, often performed in
an acute setting, cannot be always provided in the hospices,
contributing to late referrals. This information should be
assessed in future studies to explain the pathway and timing
of patients admitted to hospices.
Despite a new law has generated much interest in palli-
ative care and pain control in Italy, also facilitating opioid
prescription, institutional indications have suggested that the
palliative care network should be formed by home care and
hospice care only, excluding the vast majority of patients
living some years or months during the course of disease.
Data from this study confirm that this approach is mislead-
ing, resulting in more expenses due to inappropriate admis-
sions in hospitals without expertise in palliative care while
excluding most patients for a large period of time for pro-
longed periods of time, when they should need a specific
help in pain and symptom management. Rather, the duration
of survival of patients enrolled in hospice programs is an
important measure to assess the appropriateness of timing of
referral of terminally ill patients to palliative care. Patients
are referred to palliative care only in the last weeks of life, as
reported in this study performed in the hospice setting, and
in other studies in home care setting [6–8]. This aspect was
also underlined in very specialized centers in other countries
[9]. In a national follow-back survey representative of Ital-
ian population, 51 % of patients died at home, meaning that
many patients were admitted to acute wards unfit to provide
end-of-life care [10]. Finally, about 25 % of patients fol-
lowed at home presented severe symptom intensity for
which home care was practically impossible, suggesting that
the best option would probably be the admission to hospices
or specialized inpatients hospital units [7]. More recently,
10 % of patients followed at home were admitted to acute
wards unfit to provide end-of-life care hospital [8]. On the
other hand, this late referral to palliative care is also in contrast
with the classical definition of palliative care provided by
WHO: “Palliative care is an approach that improves the qual-
ity of life of patients and their families facing the problem
associated with life-threatening illness, through the prevention
and relief of suffering by means of early identification and
impeccable assessment and treatment of pain and other prob-
lems, physical, psychosocial and spiritual”; “Palliative care
will enhance quality of life, and may also positively influence
the course of illness; is applicable early in the course of illness,
in conjunction with other therapies that are intended to pro-
long life, such as chemotherapy or radiation therapy, and
includes those investigations needed to better understand
and manage distressing clinical complications” [11]. Finally,
recent scientific evidence in a population subgroup confirms
this WHO statement either for quality of life as well as
survival. As compared with patients receiving standard care,
patients receiving early palliative care had less aggressive care
at the end of life but longer survival [12]. Futile treatments
should be limited [13].
As expected, most patients were admitted for pain and
symptom management, or indefinite cachexia, which should
correspond to a terminal stage of disease. The mean age of
hospice patients was relatively high. This could be
explained by a specific selection of this population, possibly
Table 3 Analysis of multiple
regression on the relation
between mean admission time in
hospice and continuous and
categorical variables
The dependent variable is the
mean admission time in hospice.
The asterisk (*) indicates statis-
tical significance SE standard
error
Independent variable Slope Coefficient (SE) Coefficient of determination R2 P
Age −0.077 (0.08) 0.0034 0.382
Gender −1.678 (1.74) 0.0030 0.427
Marital status −0.798 (0.54) 0.9620 0.198
Caregiver −2.796 (2.24) 0.8130 0.216
Hospital admission in the last
3 months
−0.181 (1.42) 0.0009 0.665
Presence of background
pain at hospice admission
−7.161 (2.10) 0.0486 0.032*
Background pain intensity
at hospice admission
−0.866 (0.51) 0.0373 0.094
Opioid doses for background
pain at hospice admission
0.002 (0.006) 0.0005 0.786
Presence of breakthrough pain
episodes at hospice admission
−6.191 (2.74) 0.0461 0.041*
Breakthrough pain intensity at
hospice admission
−1.596 (0.64) 0.1157 0.017*
Background pain intensity the
day before death
−1.133 (1.15) 0.0459 0.338
Opioid doses for background
pain the day before death
−0.007 (0.01) 0.0025 0.528
Breakthrough pain intensity
the day before death
−1.769 (1.15) 0.1053 0.141
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due to lack of geriatric long-term facilities in Italy. At
admission, one third of patients had their pain uncontrolled,
despite receiving analgesic drugs, and almost half of them
had episodes of breakthrough pain. About 60 % of patients
were receiving opioid drugs, principally parenteral mor-
phine and transdermal fentanyl. As expected, opioid doses
were significantly less than those observed in acute pallia-
tive care units [14].
The day before dying, on average of 18 days, more
patients (70 %) were receiving opioid drugs, prevalently
parenteral morphine. About one third of patients presented
episodes of breakthrough pain for which parenteral mor-
phine was prescribed (not always given). The most striking
data regarding the use of breakthrough medications were the
poor use of rapid onset opioids, possibly due to their cost
and poor confidence with the use. This confirms previous
findings reported in a survey of attitudes in treating break-
through pain in Italian hospices [15].
The frequency of palliative sedation was higher than that
reported in home care patients in a previous survey (13 %)
[16]. This possibly reflects a population selection bias and/
or attitudes in a more protected environment allowing timely
intervention. For example, in an acute palliative care setting,
the frequency of sedation was even higher, more than 50 %
of patients dying in the unit. This is explained by the
selection of patients admitted for more distressing condi-
tions and compelling criteria, as witnessed by the short
duration of sedation [17]. Duration of palliative sedation in
this study was relatively similar to that reported at home
(3.5 days on average) and drug choices were similar [16].
Conclusion
Data from hospice activities in Italy strongly suggest to
spread palliative care in other settings, other than home care
and hospice, to intercept oncologic patients in their disease
trajectory early, for example, in high volume oncologic
departments, rather than restricting the action area only in
the last weeks of life [2, 4, 18]. Amendments to the recent
law should favor anticipation of palliative–supportive care,
to correct this important gap, promoting expertise in pallia-
tive care or institution of specialized units in oncologic
departments working in a multidisciplinary model of simul-
taneous care through all the period of disease.
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